Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6211244 | AMGEN | Calcium receptor-active compounds |
Oct, 2015
(8 years ago) | |
US6313146 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(7 years ago) | |
US6011068 | AMGEN | Calcium receptor-active molecules |
Mar, 2018
(6 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6031003 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(7 years ago) | |
US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) | |
US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-200) | May 23, 2020 |
Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
M(M-101) | Feb 25, 2014 |
New Indication(I-634) | Feb 25, 2014 |
Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
Market Authorisation Date: 08 March, 2004
Treatment: Method of decreasing or reducing parathyroid hormone level; Method of modulating parathyroid hormone secretion; Method of treating hyperparathyroidism; Method of reducing serum ionized calcium level; ...
Dosage: TABLET;ORAL